Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475120 | 0.85 | TAS2R14 (0.59) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL3370087 | 0.84 | HSD17B10 (0.43) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL30377873 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL24959817 | 0.83 | CES2 (0.50) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL30519391 | 0.83 | CES2 (0.50) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| Ammonia Solution, Strong SCHEMBL28849078 | 0.83 | TAS2R14 (0.57) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL2477164 | 0.83 | CES2 (0.50) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 | |
| SCHEMBL460066 | 0.82 | KDM4E (0.69) | ALDH1A1HPGDKDM4EHSD17B10USP2 | |
| SCHEMBL2346964 | 0.81 | TDP1 (0.56) | ALDH1A1HPGDHSD17B10RXRARXRB | |
| SCHEMBL7786271 | 0.80 | PTPN1 (0.56) | ALDH1A1HPGDKDM4EHSD17B10TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20250084112-A1 | Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| CN-116003309-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0578586-B1 | Fungicidal Phenylbenzamide derivatives | RHONE POULENC AGROCHIMIE (FR) | 1997-04-09 | — | — | EP | disclosed |
| US-5514719-A | Fungicidal phenylbenzamides | RHONE-POULENC AGROCHIMIE (FR) | 1996-05-07 | — | — | US | disclosed |
| CN-1081179-A | Fungicidal agents phenylbenzamaide and preparation method thereof | RHONE POULENC AGROCHIMIE (FR) | 1994-01-26 | — | — | CN | disclosed |
| EP-0578586-A1 | Fungicidal Phenylbenzamide derivatives | RHONE-POULENC AGROCHIMIE (FR) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084112-A1 | Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases | SCN8A, SCN1A, SCN10A | ALDH1A1 1716/4885HPGD 1200/4885KDM4E 3090/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3105/4885HPGD 804/4885KDM4E 4024/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | ALDH1A1 2933/4885HPGD 549/4885KDM4E 2636/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885HPGD 754/4885KDM4E 4114/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | ALDH1A1 996/4885HPGD 2894/4885KDM4E 3698/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ALDH1A1 2665/4885HPGD 1512/4885KDM4E 1582/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | ALDH1A1 1507/4885HPGD 2085/4885KDM4E 3921/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ALDH1A1 2665/4885HPGD 1512/4885KDM4E 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.